Kirkland Advises on US$448 Million Hong Kong IPO of Everest Medicines

Kirkland has acted as the underwriters' counsel in the US$448 million IPO and listing of Everest Medicines Limited (HKSE: 1952), a biopharmaceutical company that integrates licensing, clinical development and commercialization of therapies for the needs in Greater China and emerging Asia Pacific, on the Hong Kong Stock Exchange. The listing took place on October 9, 2020.

The underwriters included Goldman Sachs, Merrill Lynch, Citigroup, China International Capital Corporation, Credit Suisse, Nomura International and Brocade River Asset Management.

Read the Everest Medicines prospectus

The Kirkland team was led by transactional partner David Zhang and capital markets partner Li-Chien Wong with assistance from capital markets partner Ben James.